申请人:Medivir AB
公开号:US20030092743A1
公开(公告)日:2003-05-15
Compounds of the formula I:
1
where;
R
1
is O, S;
R
2
is an optionally substituted nitrogen-containing heterocycle, wherein the nitrogen is located at the 2 position relative to the (thio)urea bond;
R
3
is H, C
1
-C
3
alkyl,
R
4
-R
7
are independently selected from H, C
1
-C
6
alkyl, C
2
-C
6
alkenyl, C
2
-C
6
alkynyl, haloC
1
-C
6
alkyl, C
1
-C
6
alkanoyl, haloC
1
-C
6
alkanoyl, C
1
-C
6
alkoxy, haloC
1
-C
6
alkoxy, C
1
-C
6
alkyloxy-C
1
-C
6
alkyl, haloC
1
-C
6
alkyloxy-C
1
-C
6
alkyl hydroxy-C
1
-C
6
alkyl, amino-C
1
-C
6
alkyl, carboxy-C
1
-C
6
alkyl, cyano-C
1
-C
6
alkyl, amino, carboxy, carbamoyl, cyano, halo, hydroxy, keto;
X is —(CR
8
R
9
)
n
—
R
8
and R
9
are independently H, C
1
-C
3
alkyl, OH or R
8
and R
9
together are ═O
n is 1, 2 or 3
and prodrugs and pharmaceutically acceptable salts thereof, have utility as inhibitors of HIV-1 reverse transcriptase, particularly drug escape mutants.
化合物的结构式为I:1,其中;R1为O,S;R2为可选择取代的含氮杂环,其中氮原子位于与(
硫)
脲键相对的2位置;R3为H,C1-C3烷基,R4-R7分别选自H,C1-C6烷基,C2-C6烯基,C2-C6炔基,卤代C1-C6烷基,C1-C6酰基,卤代C1-C6酰基,C1-C6氧烷基,卤代C1-C6氧烷基,C1-C6氧烷基-C1-C6烷基,卤代C1-C6氧烷基-C1-C6烷基,羟基-C1-C6烷基,
氨基-C1-C6烷基,羧基-C1-C6烷基,
氰基-C1-C6烷基,
氨基,羧基,
氨基甲酰基,
氰基,卤素,羟基,酮基;X为—(CR8R9)n—,R8和R9独立取自H,C1-C3烷基,OH,或R8和R9一起为═n为1、2或3;它们的前药和药学上可接受的盐作为HIV-1逆转录酶
抑制剂具有作用,特别是对抗药物逃逸突变体。